On April 13, about 40,000 new cases were confirmed worldwide, a marked slowdown in the past two days compared with last week. As of 19:00 on 14 April, more than 1.9 million cases had been confirmed worldwide.
Up to now, the new trend of key epidemic countries in the world is showing signs of improvement. More than 580000 confirmed cases have been confirmed in the United States, and the number of new confirmed cases in a single day has been declining since April 10. In Europe, Italy, Spain and Germany, as key epidemic countries second only to the United States, have continued to decline in recent days. In Asia, South Korea is the most effective in controlling the epidemic, and the new trend is stable and improving.
As the first country in the world to spread the new crown virus on a large scale, China has begun the research of new crown virus and vaccine research and development, and has made great progress. On April 12, the adenovirus vector recombinant new crown vaccine, developed by Academician Chen Wei of the Institute of Biological Engineering of the Academy of military Sciences, officially launched phase II clinical trials. This is the only new crown vaccine in the world that has entered phase II clinical trials. In addition, on April 13, the country's other two new crown virus. The inactivated vaccine was approved to enter the clinical trial stage. They are: the new coronavirus (COVID-19) inactivated vaccine developed by China National Pharmaceutical Group China Biological Wuhan Biological products Research Institute Co., Ltd., and the new coronavirus developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd. Inactivated Mikel Laifu. So far, three new crown vaccines have been approved for clinical trials in China. According to the statistics of the World Health Organization (WHO), at least 51 vaccine candidates are being developed around the world, and the world is speeding up the pace of exploring a new crown vaccine.
[cumulative trend of diagnosis in major overseas countries]
[trend of new diagnoses in Europe and the United States]
[trend of new diagnoses in Japan, South Korea and India]
[new trends in diagnostics in other key countries]
